Delfia prostatus

Manufactured by PerkinElmer

Sourced in Finland

DELFIA ProStatus is a fluorescence-based assay system for the quantitative detection of protein analytes. It utilizes time-resolved fluorometry technology to provide sensitive and specific measurements of target proteins in biological samples.

Automatically generated - may contain errors

Lab products found in correlation

Victor instrument, by PerkinElmer (1 mentions)

Spelling variants of this product

DELFIA Prostatus total/free PSA-Assay (7 citations) DELFIA Prostatus assay (2 citations) DELFIA Prostatus PSA Free/Total PSA (2 citations)

4 protocols using delfia prostatus

Multiplexed Measurement of Kallikrein Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

We measured four kallikrein markers—human kallikrein-related peptidase 2 (hK2) and total, free, and intact PSA—in cryopreserved (below −70°C) heparin anticoagulated blood plasma from cases and controls. All laboratory analyses were conducted blind to outcome and case-control status. We measured total and free PSA with the dual-label DELFIA ProStatus assay (PerkinElmer, Turku, Finland) [22 (link)], calibrated against the World Health Organization (WHO) 96/670 (PSA-WHO) and WHO 68/668 (free PSA-WHO) standards, in previously unthawed cryopreserved heparin anticoagulated blood plasma. Intact PSA and hK2 were measured using F(ab′)2 fragments of the monoclonal capture antibodies to reduce the frequency of nonspecific assay interference [23 (link)].

Sjoberg D.D., Vickers A.J., Assel M., Dahlin A., Poon B.Y., Ulmert D, & Lilja H.G. (2018). Twenty year Risk of Prostate Cancer Death by Midlife Prostate specific Antigen and a Panel of Four Kallikrein Markers in a Large Population based Cohort of Healthy Men. European urology, 73(6), 941-948.

+ Open protocol

+ Expand

Prostate-Specific Antigen Measurement

Check if the same lab product or an alternative is used in the 5 most similar protocols

All laboratory analyses were conducted blind to outcome and case-control status. We measured total and free PSA with the dual-label DELFIA ProStatus assay (PerkinElmer, Turku, Finland), calibrated against the World Health Organization (WHO) 96/670 (PSA-WHO) and WHO 68/668 (free PSA-WHO) standards, in previously unthawed cryopreserved heparin anticoagulated blood plasma. Intact PSA and hK2 were measured using F(ab’)2 fragments of the monoclonal capture antibodies to reduce the frequency of nonspecific assay interference and carried out as previously reported^{21 (link),22 (link)}.

Klein R.J., Vertosick E., Sjoberg D., Ulmert D., Rönn A.C., Häggström C., Thysell E., Hallmans G., Dahlin A., Stattin P., Melander O., Vickers A, & Lilja H. (2022). Prostate cancer polygenic risk score and prediction of lethal prostate cancer. NPJ Precision Oncology, 6, 25.

+ Open protocol

+ Expand

Measuring Kallikrein Markers in Blood Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

We measured four kallikrein (KLK) markers—human kallikrein-related peptidase 2 (hK2) and total, free, and intact PSA—in cryopreserved blood samples from cases and controls. All laboratory analyses were conducted blind to outcome and case–control status. We measured total and free PSA with the dual-label DELFIA ProStatus assay (PerkinElmer, Turku, Finland) [6 (link)], calibrated against the World Health Organization (WHO) 96/670 (PSA-WHO) and WHO 68/668 (free PSA-WHO) standards, in previously unthawed cryopreserved heparin anticoagulated blood plasma. Intact PSA and hK2 were measured using F(ab′)2 fragments of the monoclonal capture antibodies to reduce the frequency of nonspecific assay interference [7 (link)].

Stattin P., Vickers A.J., Sjoberg D.D., Johansson R., Granfors T., Johansson M., Pettersson K., Scardino P.T., Hallmans G, & Lilja H. (2015). Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case–Control Study. European urology, 68(2), 207-213.

+ Open protocol

+ Expand

Immunoassay Measurement of Prostate Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

All immunoassay measurements of PSA, hK2, and MSP were conducted blinded on the Victor instrument (Perkin-Elmer, Turku, Finland) using the dual-label DELFIA Prostatus® total/free PSA-Assay (Perkin-Elmer, Turku, Finland) calibrated against the World Health Organization (WHO) 96/670 (PSA-WHO) and WHO 68/668 (free PSA-WHO) standards. Production and purification of the polyclonal rabbit anti-MSP antibody, protocols for biotinylation and Europium labeling of the anti-MSP antibody, and performance of the MSP-immunoassay were performed as previously reported [69 (link)]. Duplicate samples were read, average and standard deviation were plotted.

Wang X., Hayes J.E., Xu X., Gao X., Mehta D., Lilja H.G, & Klein R.J. (2020). Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing. Gene, 768, 145265.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!